JCO ® Precision Oncology (JCO PO) Publishes Study Demonstrating Clinical Validity and Utility of OncoHost's PROphet® NSCLC Test

Hope for metastatic patients as PROphet® blood test guides first-line treatment selection by identifying individuals with the highest likelihood of benefit from PD-1/PD-L1 inhibitors BINYAMINA, Israel and CARY, N.C., March 21, 2024 /PRNewswire/ -- OncoHost, a technology company...
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Tags: TRI Source Type: news